Alexion Pharmaceuticals Inc

0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS

Case Summary
Company Name: Alexion Pharmaceuticals Inc
Stock Symbol : NASDAQ: ALXN
Class Period Start: 02/10/2014
Class Period End: 11/09/2016
Lead Plaintiff motion: 01/17/2017
Date Filed: 11/17/2016
Type of Case: Securities Class Action
Court: U.S. District Court for the Southern District of New York
Summary:

Thieler Law Corp advises investors with losses exceeding $100,000 of the January 17, 2017 lead plaintiff deadline in a class action lawsuit filed against Alexion Pharmaceuticals Inc (NASDAQ: ALXN) (“Alexion” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Alexion Pharmaceuticals Inc securities between February 10, 2014 and November 9, 2016, have until January 17, 2017 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Alexion Pharmaceuticals Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Alexion employed improper sales practices with respect to its product Soliris; that the Company's revenues from Soliris sales were unlikely to be sustainable; and as a result, the Company's public statements were materially false and misleading at all relevant times.

On December 12, 2016, Alexion revealed that David Hallal, the Company's CEO and Vikas Sinha, the Company's CFO have both resigned effective immediately.  These resignations come amid allegations that Alexion engaged in improper sales practice on its drug Soliris.

Following this news, NASDAQ: ALXN dropped 15% during intraday trading on December 12, 2016.

If you were negatively impacted by your investment in Alexion Pharmaceuticals Inc securities between February 10, 2014 and November 9, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185

Transactions
Buy date (mm/dd/yyyy) Number of shares Price per share
Sell date (mm/dd/yyyy) Number of shares Price per share
Please wait...